Humberto C. Antunes is President and CEO of Galderma, one of the world’s largest companies dedicated to supporting healthcare professionals and meeting the needs of patients seeking medical solutions to their skin, hair and nail conditions. After joining Galderma in 1997 to head up its Latin American business, he went on to manage Galderma’s North American operations, and was appointed as President and CEO of Galderma in 2004. In addition to his current functions, Humberto was appointed as President and CEO of Nestlé Skin Health S.A. in July 2014, the holding that owns Galderma operations throughout the world.
An active member of the American Academy of Dermatology, the American Skin Association and the Women’s Dermatologic Society, he also volunteers in committees and acts as speaker in business and scientific forums, earning him several industry service awards.
After obtaining a degree in Business Administration from the University of Nebraska, Mr. Antunes continued his management studies at the Johnson Graduate School of Management, Cornell University, Ithaca NY, and the IMD Lausanne, Switzerland.
Mr. Antunes is fluent in six languages. He is married and lives in Lausanne.
Mr. Antunes has created a blog where he frequently posts content on a wide range of topics, hoping to interest and inform people on medical solutions for the skin.
David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, which is expected to reach $7 billion in sales in 2014. Allergan is currently the fastest growing global ophthalmic company and holds leadership positions in multiple specialty areas: ophthalmics, medical aesthetics, medical dermatology, neurology, and urologics.
As Chairman of the Board and Chief Executive Officer of Allergan, Mr. Pyott has driven long-term growth and stockholder value through a sophisticated customer-centric business model focused on meeting and exceeding the expectations of physicians and delivering products that help improve the lives of patients. As a leader who is committed to scientific advancement, and as an innovator with a strong background in consumer marketing, Mr. Pyott recognized the potential of BOTOX® to be used for cosmetic and therapeutic purposes. Today, BOTOX® is one of the company's most renowned products and is now recognized by regulatory authorities as an effective treatment for more than 27 different indications across approximately 88 countries. Under Mr. Pyott's leadership, Allergan's investment in Research & Development has increased from less than $100 million in 1998 to approximately $1 billion in 2013, and the company has created an industry-leading Research & Development pipeline with more than 180 product and indication approvals secured worldwide in 2013 alone.
With a keen emphasis on achieving category leading market positions, in March 2006, Allergan acquired Inamed Corp. for over $3 billion to create the world's largest medical aesthetics company. In 2007, Allergan acquired Groupe Laboratories Cornéal in France, and in 2012, acquired SkinMedica, Inc., making Allergan the fastest growing company in the US physician dispensed topical aesthetics category. More recently, the company acquired MAP Pharmaceuticals for its inhaled migraine therapy technology and TARIS Biomedical's® lead program, LiRIS®, currently in Phase 2 trials for the treatment of interstitial cystitis/ bladder pain syndrome (IC/BPS).
In 2006, Mr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgement of his contribution to British business excellence and management skills in the United States. Mr. Pyott has also been recognized for his financial and leadership accomplishments by many prominent and well-respected business organizations. Mr. Pyott was recognized by Harvard Business Review as one of "The 100 Best Performing CEOs in the World" in 2014 (ranked #4), 2013 (ranked #26) and 2009 (ranked #50), and was recognized as the "#1 CEO in Specialty Pharmaceuticals" by Institutional Investor magazine in 2005, 2007, and the "Best CEO Healthcare – Pharmaceuticals" in 2012 and 2013. In 2010, he received an honorary degree, the UCI Medal, and the Moacyr Gold Medal for services to Brazilian ophthalmology.
Before joining Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG, working over 17 years in several positions in strategic planning, marketing and general management around the world.
Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.
Mr. Pyott is a member of the Board of Directors of Avery Dennison Corporation. He serves on the Board, on the Executive Committee and as Board Secretary of the Biotechnology Industry Organization. In addition, he is Vice Chairman of the Board of Trustees of Chapman University, President of the ICOFoundation and is on the Dean's Advisory Board of The Paul Merage School of Business at the University of California Irvine.
Gene is a co-founder of Dermira, Inc., its Chief Medical Officer and a member of its board of directors. Prior to founding Dermira, Gene served as a member of Peplin’s board of directors, and its President and Chief Medical Officer, until its acquisition by LEO Pharma in 2009. Gene was also the Chief Executive Officer of Neosil Inc., and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, Gene served as the Dean of the Stanford University School of Medicine and as Chair of the Department of Dermatology at the Stanford University School of Medicine. Gene is a Lucy Becker Professor, Emeritus, in the School of Medicine at Stanford University, a position he has held since 2002.
Gene has served on the boards of directors of a number of public and private companies. He is currently a member of the boards of directors of Medgenics, Inc., Dr. Tattoff, Inc., First Wave Technologies, Inc., Cerecor, Inc., and Kadmon Corporation. Gene has previously served as a member of the boards of directors of Protalex, Inc., Vyteris, Inc., Peplin, PetDRx, Inc., Arbor Vita Corp., Patient Safety Technologies, Inc., MediSync Bioservices and Modigene Inc. (now PROLOR Biotech, Inc.).
Gene was a National Institutes of Health funded investigator for 25 years and served on numerous review groups for the NIH. Gene has been elected to several societies, including the Institute of Medicine of the National Academy of Sciences. Gene received a B.S. and an MD from Northwestern University.
Jim DiBiasi is known for his ability to lead diverse teams and help them succeed at decisive communications opportunities. Jim provides strategic and tactical communications counsel and coaching to top executives, scientists, and doctors at pharmaceutical, biotech, and device companies. Jim has guided scientists and executives through numerous regulatory communications, such as pre-NDA and IND meetings and challenging advisory committee meetings. He has been instrumental in developing 3D's proprietary process and communications tools to help clients analyze their audiences and prepare for their communications in more effective ways. A gifted communicator, Jim has practical experience in front of the camera and before live audiences. He has crafted and delivered hundreds of presentations and served as a legislative lobbyist and media spokesperson for Fortune 200 companies, leading them through numerous communications crises.
Learn more about 3D Communications.
Lynn A. Drake, MD, is Lecturer at Harvard Medical School, on the Dermatology Faculty at Massachusetts General Hospital (MGH) and is Director of Policy and Business Development for the Wellman Center of Photomedicine at MGH in Boston. She has a Doctor of Medicine (MD) degree, a Master of Arts (MA) degree in Mathematics, a Bachelor of Arts (BA) degree in Mathematics, and a Bachelor of Arts (BA) in Chemistry. She is board certified in Dermatology and Dermatopathology. Dr. Drake is a graduate of the Advanced Management Program (AMP) at Harvard Business School and devoted her sabbatical year to the study of medicine and business. Dr. Drake is Past President of the American Academy of Dermatology and the Women’s Dermatology Society. She has served on the National Advisory Board for the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), the Board of Directors of the American Society of Dermatologic Surgery, and as a Robert Wood Johnson Health Policy Fellow and Congressional Fellow in Washington, DC, sponsored by the Institute of Medicine. She received a Presidential Appointment as a US Delegate to the World Health Organization and was on the National Policy Forum Council for Health Care Reform. She has also served as a Trustee for the Dermatology Foundation and on the Board of Directors for the Council for Nail Disorders and the American Acne and Rosacea Society. Dr. Drake previously served as Professor and Chair of the Department of Dermatology at University of Oklahoma Health Sciences Center, and Deputy Chair of the Department of Dermatology at Harvard Medical School where she was also Director of the Dermatology Clinical Investigation Unit. She has been on the faculty of Emory University, was a partner in the Emory Clinic, and served as Chief of the Dermatology Service at the VA Medical Center in Atlanta. She currently Chairs the Food and Drug Administration’s (FDA’s) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) at the Center for Drug Evaluation and Research (CDER), is a consultant to the FDA, and has served on multiple FDA Advisory Board panels.
Dr. Drake was named as one of the 100 Best Doctors in America, Outstanding Young Women of America, and received the Outstanding Alumnus Award from the University of Tennessee College Of Medicine and the Outstanding Alumnus Achievement Award from Adams State University in Colorado where she was invited to deliver the commencement address in 2009. Dr. Drake received the Bergfeld Award for Leadership and Vision and the Rose Hirschler Award from the Women’s Dermatologic Society. She was elected to membership in the American Dermatological Association and has received honorary membership in the German, Canadian, and Mexico Dermatological Society(s). She is recipient of several named lectureships, is the author of over 100 papers, and has been a visiting professor at over 60 universities. She has presented over 400 invited national and international lectures and has been a frequent contributor to multiple media sources.
Dr. Dubin has advised life sciences companies and investors for nearly 20 years and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. He also leads Leerink Partners' dermatology and medical aesthetics advisory practice and has expertise in executing crossover private placements and Form 10 alternative go-public transactions.
In 1996, he founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He serves as a director of Living Proof and an advisor to SKS Ocular. He has also served as Chairman of MetaWorks which was sold to UBC in 2005.
Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women's Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.
Mary Fisher brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, a biotechnology company focused on developing products for the treatment of central nervous system disorders. There, she helped execute the company’s restructuring, initial public offering and a $50 million acquisition that transitioned Acorda from a developmental platform to a commercial stage operation. Ms. Fisher has served as a Pharmaceutical Consultant for companies such as Acorda Therapeutics and Roche Diagnostics and specialized in commercialization strategy, resource and outsource planning, pricing strategy and tactics, distribution planning, managed care contracting and forecasting. Previously, she held the role of Vice President, Strategic Healthcare and Commercial Operations at Cephalon, Inc., and Manager, Communications at Immunex. She currently serves as a Board Member of Zeltiq (ZLTQ), and Ovascience (OVAS), as well as the Neuroscience Nursing Foundation and is a Member of the Women’s Dermatological Society and the Dermatology Foundation Leader’s Society.
Jim has been with Technology Partners since 2002. Jim leads the firm's efforts in Consumer Medicine, investing in both medical device and biopharmaceutical companies.
He serves on the boards of Essentialis, ForSight VISION5, Revance Therapeutics (RVNC), Transcend Medical, and TRIA Beauty, while also having led Technology Partners' investment in companies that have since been acquired: Iomai (IOMI - acquired by Intercell AG), Cadence Pharmaceuticals (CADX - acquired by Mallinkrodt), Incline Therapeutics (acquired by The Medicines Company - MDCO). Jim is also an advisor to the Lester Center at University of California, Berkeley and the National Science Foundation (NSF) in Washington, DC.
Previously, Jim was Managing Director at CIT Venture Capital, leading the group's effort in Life Science investing. Also, Jim was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Jim earned a BS from Duke University and an MA and a PhD from Harvard University in biology. He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley. Jim has published several research papers and had his research highlighted in major media outlets including: Nature, The New York Times, Scientific American, and CNN.
Mr. Heron joined Frazier Healthcare in 1999 as an associate and became a General Partner in 2005. Mr. Heron is a member of the firm's Biopharma Venture team. He focuses on early and late-stage private and public biotechnology and specialty pharmaceutical investments. He has been active in forming companies and founding investments including Marcadia Biotech (sold to Roche in 2010), a diabetes and obesity company, Calixa (sold to Cubist in 2009), Cerexa (sold to Forest in 2007), both anti-infectives companies; and Trubion Pharmaceuticals, next generation antibody therapeutics (sold to Emergent BioSolutions in 2010). In specialty pharmaceuticals, he led Frazier’s involvement in a respiratory company, MedPointe (sold to Meda AB in 2007).
He is currently on the boards of Collegium, Precision Dermatology, QuatRx, Silvergate, Tobira and VentiRx.
Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.'s West Coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales force optimization, corporate partnering and research prioritization. He was a Phi Beta Kappa graduate and Morehead Scholar at the University of North Carolina at Chapel Hill and holds an MBA from Harvard Business School.
Peter Nicholson has worked in the biopharmaceutical and medical device industries for over 25 years. He is responsible for the worldwide strategy and business development functions at Galderma S.A., the dermatology-focused operating company of Nestlé Skin Health, which he joined in 2007. Previously he was Vice President, Corporate Development for Mentor Corporation where he successfully divested the company's urology business and refocused its strategy on the aesthetic business, which ultimately led to its acquisition by Johnson & Johnson. He served in a similar role at Inamed where he refined the company's strategy and successfully executed a number of business development agreements and revitalized the company's international presence prior to its acquisition by Allergan.
Nicholson worked at Amgen for six years in roles of increasing responsibility in product development and product licensing and was responsible for starting and managing the company's venture program. He worked at two small medical device companies, Telios and Advanced Tissues Sciences where he was a team-member focused on developing products addressing unmet needs for wound healing and burns. He pursued research at Triton Biosciences and Allergenetics where he was focused on identifying, isolating and characterizing new growth factors.
Mr. Nicholson received a master's degree in business administration from the University of California at Los Angeles where he won the 19th annual Knapp New Ventures Competition. He was a co-founder and Chief Executive Officer of Blue Heron Biotechnology, a genomics company which he grew from two to 33 employees and a successful commercial launch. He has a Bachelor of Arts degree in biochemistry with an emphasis on immunology from the University of California at Berkeley, where he did post-graduate research in the laboratory of Dr. Robert I. Mishell.
David has over 25 years of experience in the pharmaceutical industry, serving in leadership roles spanning early discovery and development at Eli Lilly and GlaxoWellcome to Global Product Strategy at GlaxoSmithKline. David also has extensive licensing, acquisition and divestment experience ranging from establishment of joint research programs to purchase of product portfolios and multi-billion dollar company acquisitions as the lead for the cardiovascular, metabolic and urogenital therapy areas for and Worldwide Business Development at GSK. David is currently Senior Director of Global Business Development and Licensing at Stiefel, a GSK company. There he is responsible for licensing and acquisition of new technology platforms, development programs, and marketed products for both the prescription dermatology and consumer skin health businesses. He has also lead the divestiture of a number of tail products and off-strategy product portfolios.
David received his PhD in Pharmacology from the Medical University of South Carolina and is the author of over 50 peer-reviewed publications and 50 scientific abstract and presentations.
Dr. Schiff joined Aisling in September of 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of Agile Therapeutics, ARMGO Pharma, PowerVision and ZELTIQ Aesthetics. Prior board service includes Adams Respiratory Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix and Quintiles (board observer). He is a long-time supporter and board member of the Visiting Nurse Service of New York.
Dr. Schiff received his MD from Cornell University Medical College, his MBA from Columbia University, and his B.S. with honors in Neuroscience from Brown University.
David Steinberg joined Jefferies as Managing Director and Senior Research Analyst covering the Specialty Pharmaceuticals sector in January 2014. Previously he was a Managing Director at Deutsche Bank (formerly Alex. Brown) for 15 years. David was one of the first analysts on Wall Street to identify Specialty Pharma as a major growth opportunity for the investment community. He has regularly been voted to the Institutional Investor "All American Research Team", including each of the seven past years. He has also been selected to the Wall Street Journal's "Best on the Street" survey for stock picking.
David's research on various topics within the global drug industry has been frequently referenced in such national publications as Barron's, The New York Times, and Fortune. David has been involved with numerous dermatology/aesthetics focused companies during his career. Selected companies he has covered include Allergan, Anacor, Collagenex, Medicis, Penederm, Perrigo and Valeant.
David received a B.A. from Colby College and an MBA from the Harvard Business School.
Thorsten was appointed Senior Vice President of New Product Discovery, a business unit with more than 200 dedicated scientists and specialists at LEO Pharma in January 2013. In this role, the priorities for Thorsten Thormann have been to continue the building of a strong R&D project pipeline at LEO Pharma.
Prior to this, Thorsten held a double role of Director of Biological Research and Director of Pharmaceutical Technologies, respectively. Here he was responsible for disease specific experimental platforms linking biochemistry and exploratory clinical testing as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and user experience. Thorsten has also held the position as Head of Department, Molecular Biomedicine, and Head of Section for Product Reprofiling.
Throughout these jobs, Thorsten has gained insights into the importance of having strong ideation processes to create confidences in new targets and concepts as well as establishing high value of life cycle management and product improvements to meet real patient needs.
Thorsten Thormann has a MSc in Chemistry from University of Roskilde and a PhD in Protein Biology from University of Copenhagen.
Dr. Walker is an independent consultant and the immediate past director of the Division of Dermatology and Dental Products (DDDP) at the Food and Drug Administration. From 2006 – 2014 she led this division of over 40 senior physicians, scientists and staff with responsibilities for review of New Drug Applications, Biologics Licensing Applications, Investigational New Drug Applications, labeling supplements, Pediatric Study Plans, Risk Evaluation and Mitigation Strategies and other regulatory submissions. Responsibilities also included oversight of the divisions meetings with industry regarding both pre and post market issues; advisory committee preparation; drafting, editing and implementation of guidances; and leading various cross-discipline and cross-center teams.
Dr. Walker is a fellow of the American Academy of Dermatology, a member of the American Dermatological Association, and is board certified in Dermatology (1990). She has an active medical license in Maryland. Before going to FDA she was Chief of the Dermatology Section at the VA in Martinez, CA.
Dr. Walker's experience includes18 years at FDA serving in multiple leadership positions across FDA Centers, including medical reviewer, Lead Medical Officer, and Division Director (DDDP) in the Center for Drug Evaluation and Research (CDER); detail as acting deputy director in the Division of General, Reconstructive, and Neurological Devices the Center for Devices and Radiologic Health (CDRH); Associate Director for Clinical Affairs in the Office of Nutritional Products, Labeling, and Dietary Supplements; and Director of the Division of Dietary Supplement Programs in the Center for Food Safety and Nutrition (CFSAN).
Dr. Walker received her BS from the University of Michigan and her MD from the Uniformed Services University School of Medicine, and served as a medical officer in the US Navy with several ship deployments and service with the US Marine Corps.
Dr. Walker currently provides independent consulting services as Susan J. Walker Consulting, LLC.
Dr. Whitcup is the Executive Vice President, R&D and Chief Scientific Officer at Allergan. He is on the faculty at the Jules Stein Eye Institute/David Geffen School of Medicine at UCLA and also serves as a Director on the Board of Semnur Pharmaceuticals and as a member of the Biology Chair's Council at Caltech. He previously served as a Director at Avanir Pharmaceuticals and Questcor Pharmaceuticals.
Dr. Whitcup graduated from Cornell University Medical College and completed residency training both in internal medicine at UCLA Medical Center and in ophthalmology at the Massachusetts Eye and Ear Infirmary-Harvard Medical School. He then received fellowship training in uveitis and ocular immunology at the National Eye Institute at the National Institutes of Health. Prior to coming to Allergan, Dr. Whitcup was Clinical Director of the National Eye Institute, and also served as head of the Clinical Branch and Director of the uveitis and ocular immunology fellowship program. Dr. Whitcup also served as Chair of the NIH Medical Executive Committee.
Dr. Whitcup currently directs Allergan's drug discovery efforts, medical device research, and the worldwide clinical development programs that include ophthalmology, neurosciences, dermatology, plastic surgery, and urology. He is also in charge of Allergan's global medical affairs organization. Dr. Whitcup is an author on over 150 scientific articles, book chapters, and a textbook on ocular inflammatory disease.